As expected, the model predicts that temozolomide (TMZ) will have a stronger antitumor effect (lower IC50) in glioma patients with MGMT promoter methylation, which reduces expression of the DNA repair enzyme MGMT (Figure 1(BI)). The gene discussed is MGMT; the disease is glioma.